Compare PCVX & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | BLCO |
|---|---|---|
| Founded | 2013 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.1B |
| IPO Year | 2020 | 2022 |
| Metric | PCVX | BLCO |
|---|---|---|
| Price | $56.05 | $16.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $109.00 | $19.04 |
| AVG Volume (30 Days) | ★ 1.2M | 288.1K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $7.71 |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $39.87 | $13.77 |
| 52 Week High | $65.00 | $18.92 |
| Indicator | PCVX | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 49.12 |
| Support Level | $52.18 | $16.94 |
| Resistance Level | $58.77 | $17.21 |
| Average True Range (ATR) | 2.19 | 0.39 |
| MACD | -0.27 | -0.03 |
| Stochastic Oscillator | 30.24 | 45.28 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.